Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lacsap-GG** is an oral fixed-dose sachet formulation marketed by Vilco Laboratories for chronic constipation. It combines lactitol, an osmotic laxative that retains water in the intestinal lumen; ispaghul, a water-absorbing bulk-forming fiber; and the probiotic strain *Lactobacillus rhamnosus* GG, intended to support restoration of gut flora. The manufacturer describes the product as providing relief of constipation and bloating while improving bowel movements and gut health. ([vilcolabs.com](https://vilcolabs.com/product/new-innovative-products/lacsap-gg-2/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lacsap-GG.